NZ514697A - Substituted benzolactam compounds - Google Patents
Substituted benzolactam compoundsInfo
- Publication number
- NZ514697A NZ514697A NZ514697A NZ51469700A NZ514697A NZ 514697 A NZ514697 A NZ 514697A NZ 514697 A NZ514697 A NZ 514697A NZ 51469700 A NZ51469700 A NZ 51469700A NZ 514697 A NZ514697 A NZ 514697A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- disorder
- disorders
- oxo
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13285899P | 1999-05-06 | 1999-05-06 | |
| PCT/IB2000/000461 WO2000068224A1 (en) | 1999-05-06 | 2000-04-13 | Substituted benzolactam compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ514697A true NZ514697A (en) | 2004-04-30 |
Family
ID=22455915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ514697A NZ514697A (en) | 1999-05-06 | 2000-04-13 | Substituted benzolactam compounds |
Country Status (40)
| Country | Link |
|---|---|
| EP (1) | EP1175417B1 (xx) |
| JP (1) | JP2002544128A (xx) |
| KR (1) | KR20020015319A (xx) |
| CN (1) | CN1349527A (xx) |
| AP (1) | AP2001002314A0 (xx) |
| AR (1) | AR036320A1 (xx) |
| AT (1) | ATE257478T1 (xx) |
| AU (1) | AU3572800A (xx) |
| BG (1) | BG106141A (xx) |
| BR (1) | BR0010673A (xx) |
| CA (1) | CA2373079A1 (xx) |
| CR (1) | CR6505A (xx) |
| CZ (1) | CZ20013977A3 (xx) |
| DE (1) | DE60007625T2 (xx) |
| DK (1) | DK1175417T3 (xx) |
| DZ (1) | DZ3040A1 (xx) |
| EA (1) | EA200101050A1 (xx) |
| EE (1) | EE200100586A (xx) |
| ES (1) | ES2211520T3 (xx) |
| GE (1) | GEP20043224B (xx) |
| GT (1) | GT200000063A (xx) |
| HK (1) | HK1046144A1 (xx) |
| HR (1) | HRP20010821A2 (xx) |
| HU (1) | HUP0201135A3 (xx) |
| IL (1) | IL145945A0 (xx) |
| IS (1) | IS6122A (xx) |
| MA (1) | MA26731A1 (xx) |
| MY (1) | MY133207A (xx) |
| NO (1) | NO20015395L (xx) |
| NZ (1) | NZ514697A (xx) |
| OA (1) | OA11864A (xx) |
| PA (1) | PA8494901A1 (xx) |
| PE (1) | PE20010119A1 (xx) |
| PL (1) | PL351919A1 (xx) |
| PT (1) | PT1175417E (xx) |
| TN (1) | TNSN00095A1 (xx) |
| TR (1) | TR200103222T2 (xx) |
| UY (1) | UY26135A1 (xx) |
| WO (1) | WO2000068224A1 (xx) |
| ZA (1) | ZA200109116B (xx) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0108982D0 (en) | 2001-04-10 | 2001-05-30 | Merck Sharp & Dohme | Therapeutic agents |
| EP1460061A4 (en) * | 2001-12-27 | 2006-05-31 | Toray Finechemicals Co Ltd | PROCESS FOR PRODUCING 1-ALCOXYCARBONYL SATURATED NITROGENIC HETEROCYCLIC DERIVATIVE |
| EP1613348B1 (en) | 2003-03-12 | 2010-06-23 | The Arizona Board of Regents on Behalf of the University of Arizona | Methods for modulating angiogenesis with apelin compositions |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| WO2009109001A1 (en) * | 2008-03-04 | 2009-09-11 | Adelaide Research & Innovation Pty Ltd | Method for preventing and/or treating a disease, condition or state associated with reduced dopaminergic neuron function |
| JP6156074B2 (ja) * | 2013-11-08 | 2017-07-05 | 住友化学株式会社 | スクシンイミド化合物及びその用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE194340T1 (de) * | 1992-12-10 | 2000-07-15 | Pfizer | Aminomethylen substituierte heterocyclische verbindungen und ihre verwendung alssubstanz p antagonisten |
| ES2155601T3 (es) * | 1995-07-07 | 2001-05-16 | Pfizer | Compuestos de benzolactama sustituidos como antagonistas de la sustancia p. |
| TW340842B (en) * | 1995-08-24 | 1998-09-21 | Pfizer | Substituted benzylaminopiperidine compounds |
| ES2180693T3 (es) * | 1995-12-21 | 2003-02-16 | Pfizer | 3-((bencil 5-sustituido)amino)-2-fenilpiperidinas como antagonistas de la sustancia p. |
| TW426667B (en) * | 1997-11-19 | 2001-03-21 | Pfizer | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists |
-
2000
- 2000-04-13 GE GEAP20006190A patent/GEP20043224B/en unknown
- 2000-04-13 PT PT00914335T patent/PT1175417E/pt unknown
- 2000-04-13 AP APAP/P/2001/002314A patent/AP2001002314A0/en unknown
- 2000-04-13 NZ NZ514697A patent/NZ514697A/en unknown
- 2000-04-13 KR KR1020017014110A patent/KR20020015319A/ko not_active Application Discontinuation
- 2000-04-13 IL IL14594500A patent/IL145945A0/xx unknown
- 2000-04-13 EA EA200101050A patent/EA200101050A1/ru unknown
- 2000-04-13 DE DE2000607625 patent/DE60007625T2/de not_active Expired - Fee Related
- 2000-04-13 TR TR2001/03222T patent/TR200103222T2/xx unknown
- 2000-04-13 HU HU0201135A patent/HUP0201135A3/hu unknown
- 2000-04-13 DK DK00914335T patent/DK1175417T3/da active
- 2000-04-13 EE EEP200100586A patent/EE200100586A/xx unknown
- 2000-04-13 CZ CZ20013977A patent/CZ20013977A3/cs unknown
- 2000-04-13 AU AU35728/00A patent/AU3572800A/en not_active Abandoned
- 2000-04-13 CA CA002373079A patent/CA2373079A1/en not_active Abandoned
- 2000-04-13 CN CN00807267A patent/CN1349527A/zh active Pending
- 2000-04-13 WO PCT/IB2000/000461 patent/WO2000068224A1/en not_active Application Discontinuation
- 2000-04-13 OA OA1200100264A patent/OA11864A/en unknown
- 2000-04-13 ES ES00914335T patent/ES2211520T3/es not_active Expired - Lifetime
- 2000-04-13 AT AT00914335T patent/ATE257478T1/de not_active IP Right Cessation
- 2000-04-13 PL PL00351919A patent/PL351919A1/xx not_active Application Discontinuation
- 2000-04-13 EP EP00914335A patent/EP1175417B1/en not_active Expired - Lifetime
- 2000-04-13 JP JP2000616198A patent/JP2002544128A/ja active Pending
- 2000-04-13 BR BR0010673-9A patent/BR0010673A/pt not_active IP Right Cessation
- 2000-05-03 MA MA25966A patent/MA26731A1/fr unknown
- 2000-05-03 TN TNTNSN00095A patent/TNSN00095A1/fr unknown
- 2000-05-03 UY UY26135A patent/UY26135A1/es not_active Application Discontinuation
- 2000-05-03 PA PA20008494901A patent/PA8494901A1/es unknown
- 2000-05-03 DZ DZ000082A patent/DZ3040A1/xx active
- 2000-05-04 MY MYPI20001922A patent/MY133207A/en unknown
- 2000-05-04 AR ARP000102150A patent/AR036320A1/es unknown
- 2000-05-05 GT GT200000063A patent/GT200000063A/es unknown
- 2000-05-05 PE PE2000000418A patent/PE20010119A1/es not_active Application Discontinuation
-
2001
- 2001-10-23 IS IS6122A patent/IS6122A/is unknown
- 2001-11-05 NO NO20015395A patent/NO20015395L/no not_active Application Discontinuation
- 2001-11-05 ZA ZA200109116A patent/ZA200109116B/en unknown
- 2001-11-06 HR HR20010821A patent/HRP20010821A2/hr not_active Application Discontinuation
- 2001-11-19 CR CR6505A patent/CR6505A/es not_active Application Discontinuation
- 2001-11-23 BG BG106141A patent/BG106141A/bg unknown
-
2002
- 2002-10-29 HK HK02107807.6A patent/HK1046144A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6180647B1 (en) | Substituted benzolactam compounds as substance P antagonists | |
| EP1562945B1 (en) | 1,4-diazabicyclo(3,2,2)nonane derivatives, preparation and therapeutical use thereof | |
| EP0460062B1 (en) | Huperzine a analogs | |
| FR2563521A1 (fr) | Derives de la 1,4-dihydro-4-oxonaphtyridine et leurs sels, procede pour leur production et agents antibacteriens les contenant | |
| US20030105124A1 (en) | Substituted benzolactam compounds | |
| CA2445888A1 (en) | Chiral, broad-spectrum antibacterial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation and compositions | |
| JP2005511743A (ja) | 新世代の三重標的化したキラルな広域スペクトラム抗菌性の７位置換ピペリジノ−キノロンカルボン酸誘導体、その調製方法、組成物、および医薬としての使用 | |
| NZ514697A (en) | Substituted benzolactam compounds | |
| EP2496579B1 (en) | 1-substituted 2-azabicyclo[3.1.1]heptyl derivatives useful as nicotinic acetylcholine receptor modulators for treating neurologic disorders | |
| EP2061461B1 (en) | 3-azabicyclo[4.1.0]heptane derivatives for the treatment of depression | |
| US5604241A (en) | Substituted benzylaminoquinuclidines as substance P antagonists | |
| US6288225B1 (en) | Substituted benzolactam compounds as substance P antagonists | |
| JP2003500405A (ja) | １−トリフルオロメチル−４−ヒドロキシ−７−ピペリジニル−アミノメチルクロマン誘導体類 | |
| WO2009056520A1 (en) | Azabicyclo[3.2.1]octane derivatives | |
| WO2009027293A1 (en) | Compounds | |
| MXPA01011367A (en) | Substituted benzolactam compounds | |
| US6143767A (en) | Piperidinylamino tricyclic compounds as substance P antagonists | |
| CA1334413C (en) | Amino-substituted bridged azabicyclic quinolone carboxylic acids and esters | |
| US20020052503A1 (en) | Substituted benzolactam compounds as substance p antagonists | |
| EP2190817A1 (en) | 3-azabicyclo (4.1.0) heptane derivatives useful as norepinephrine, serotonin or dopamine reuptake inhibitors | |
| JPH03200789A (ja) | ラクタム誘導体の製造法 | |
| Ryabova et al. | Unexpected Recyclization of 1H-δ-Carbolines to Pyrrolo [1, 2-a] indoles | |
| HU205756B (en) | Process for producing quinolonecarboxylic acids substituted with azabicyclic group of bridged structure and substituted with amino group, as well as pharmaceutical compositions comprising same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| PSEA | Patent sealed |